Reward® (DQT) is a liquid concentrate containing diquat dibromide that is applied as an immersion bath treatment. DQT is available for purchase through many local farm & ranch stores or through Syngenta Crop Protection, LLC. The primary goal of field studies conducted under INAD #10-969 is to evaluate the efficacy of DQT for controlling mortality in all freshwater-reared finfish diagnosed with BGD or external flavobacteriosis. The treatment regimens allowed for DQT immersion are 1) 15 – 18 mg/L for 1 – 3 hours for 1 – 3 days; or 2) 28 mg/L for 1 hour for 1 – 3 days. The Investigational withdrawal period for DQT for adult Ictaluridae and Esocidae is 5 days; all other freshwater-reared finfish have a 30 day Investigational withdrawal period; if 17MT medicated feed is used with tilapia then the longer withdrawal period needs to be followed. The investigational withdrawal periods can be incorporated into the grow-out period. No prophylactic or preventive use of Diquat is allowed under this INAD. To participate in the INAD Program for DQT visit the data collecting site.
Please read the Study Protocol prior to any treatments. It contains the protocol, MSDS, and a copy of the forms to be used as a guide for collecting data that will be entered into the online INAD database. The FDA authorization letter(s) for this INAD is currently only available by emailing Bonnie Johnson.
INAD objective/purpose:Collect supportive and/or pivotal data needed to establish the effectiveness of diquat to control mortality caused by certain bacterial diseases.
Syngenta Crop Protection, LLC (often available from your local farm & ranch store, veterinary supply outlet, etc.)
P.O. Box 18300
Greensboro, NC 27419-8300
c/o Steve Cosky, Product Biology Lead, Syngenta
Target pathogen(s): External flavobacteriosis (e.g. bacteria responsible for bacterial gill disease, external columnaris, and external coldwater disease)
Method of administration: Immersion: flow-through or standing bath treatment
Investigational Withdrawal period:
Required test parameters:
Limitations or restrictions on use of drug:
Required INAD fee: $700/facility/year
AADAP Contact Information:
Ms. Bonnie Johnson, FWS-AADAP